In this Phase II, double-blind study of primed and unprimed children aged 18–47 months, we demonstrated that the additional B strain in QIV did not compromise immunogenicity of existing strains ...

Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced financial consultant. She has a demonstrated history of working in both institutional and retail environments, from broker-dealers ...

Background: The trivalent inactivated split-influenza vaccine, Fluarix TM has been available since 1992. Aim: To assess the safety and immunogenicity of the vaccine from studies in healthy adults ...

EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. To assess the risk of GBS with these vaccines, the FDA conducted a postmarketing ...